Medtronic Widens Parkinson’s aDBS Opportunity With Key US Approvals

‘The Largest Commercial Launch Of Brain-Computer Interface Technology Ever’

Medtronic’s US FDA approval for BrainSense aDBS and BrainSense EI software features of the Percept neurostimulator device has quickly followed CE marking in January.

More than 40,000 patients worldwide with the implanted Percept neurostimulator can have the BrainSense Adaptive deep brain stimulation (aDBS) and BrainSense Electrode Identifier (EI) software wirelessly switched on after the company received US Food and Drug Administration (FDA) approval for the two features on 24 February, after CE marking in January.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

OneCell Diagnostics – Now 1Cell.Ai - Launches Multi-Modal Cancer Diagnostic Panel OncoIncytes

22 Apr 2025

• By Natasha Barrow

OneCell Diagnostics, the Mumbai-based startup backed with $16m in series A funding, is rebranding to 1Cell.Ai to represent the firm's focus on combining deep science with AI-powered capabilities.

Abbott, J&J Reaffirm 2025 Profit Guidance Despite Growing Tariff Uncertainties

17 Apr 2025

• By Marion Webb

Abbott and J&J reassured investors they will maintain their 2025 profit forecasts. Abbott projects $5.05 to $5.25 per share and plans a new $500m investment in manufacturing and R&D sites. J&J anticipates $400m in tariff-related costs but committed $55bn in US investment over four years.

Looking Back Towards The Future

17 Apr 2025

• By Brian Bossetta

As it celebrates 75 years shaping the medtech industry, Medtronic invited Medtech Insight to its Minneapolis headquarters to get a closer look at the company’s past, what it’s working on now, and what’s on the horizon.